ghk-cu peptide cancer risk GHK-Cu Peptide Injection Before and

When the FDA places a peptide in a restricted or high-risk category [known as Category 2], it is explicitly signaling that it has identified safety concerns and that enforcement discretion does not apply. But, as Hajduczok notes, just because something is not FDA-approved doesnt mean its illegal to compound, but the restricted peptides should not be compounded

The FDA moved these peptides to Category 2 primarily due to a lack of large-scale, randomized, placebo-controlled human trials demonstrating their safety and efficacy

Topical GHK-Cu is primarily geared toward cosmetic health, namely concerning the skin and hair

According to data from Grand View Research, the global peptide market was valued at $140.86 billion in 2025 and is projected to reach $294.58 billion by 2033

Source: The potential of GHK as an anti-aging peptide (2020) Claim 2: Intranasal administration bypasses the blood-brain barrier (BBB) to enhance central nervous system (CNS) delivery